BRCAness revisited
CJ Lord, A Ashworth - Nature Reviews Cancer, 2016 - nature.com
Over the past 20 years, there has been considerable progress in our understanding of the
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …
Ewing sarcoma—diagnosis, treatment, clinical challenges and future perspectives
Ewing sarcoma, a highly aggressive bone and soft-tissue cancer, is considered a prime
example of the paradigms of a translocation-positive sarcoma: a genetically rather simple …
example of the paradigms of a translocation-positive sarcoma: a genetically rather simple …
Ewing's sarcoma
N Riggi, ML Suvà, I Stamenkovic - New England Journal of …, 2021 - Mass Medical Soc
Ewing's Sarcoma Ewing's sarcoma, an aggressive cancer of bone and soft tissue, primarily
affects children and young adults. A t (11; 22) translocation is noted in 85 to 90% of cases …
affects children and young adults. A t (11; 22) translocation is noted in 85 to 90% of cases …
The ETS family of oncogenic transcription factors in solid tumours
Findings over the past decade have identified aberrant activation of the ETS transcription
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …
An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy
YQ Wang, PY Wang, YT Wang, GF Yang… - Journal of medicinal …, 2016 - ACS Publications
Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base
excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug …
excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug …
EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Many cancer types are driven by oncogenic transcription factors that have been difficult to
drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers …
drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers …
Biology of bone sarcomas and new therapeutic developments
HK Brown, K Schiavone, F Gouin, MF Heymann… - Calcified tissue …, 2018 - Springer
Bone sarcomas are tumours belonging to the family of mesenchymal tumours and constitute
a highly heterogeneous tumour group. The three main bone sarcomas are osteosarcoma …
a highly heterogeneous tumour group. The three main bone sarcomas are osteosarcoma …
A review of soft-tissue sarcomas: translation of biological advances into treatment measures
NT Hoang, LA Acevedo, MJ Mann… - Cancer management and …, 2018 - Taylor & Francis
Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an
overall incidence of about five per 100,000 per year. While this diverse family of …
overall incidence of about five per 100,000 per year. While this diverse family of …
PARP inhibitor combination therapy
A Drean, CJ Lord, A Ashworth - Critical reviews in oncology/hematology, 2016 - Elsevier
Abstract In 2014, olaparib (Lynparza) became the first PARP (Poly (ADP-ribose)
polymerase) inhibitor to be approved for the treatment of cancer. When used as single …
polymerase) inhibitor to be approved for the treatment of cancer. When used as single …
Olaparib: first global approval
ED Deeks - Drugs, 2015 - Springer
Olaparib (Lynparza™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor
being developed by AstraZeneca for the treatment of solid tumours. The primary indication …
being developed by AstraZeneca for the treatment of solid tumours. The primary indication …